A
FDMT icon

AlphaQuest’s 4D Molecular Therapeutics FDMT Stock Holding History

AlphaQuest’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,731
Closed -$118K – 724
2025
Q4 		$118K Buy
15,731
+436
+3% +$4.42K 0.01% 1680
2025
Q3 		$133K Buy
+15,295
New +$91.4K 0.01% 1601
2025
Q2 		– Sell
-15,295
Closed -$49.4K – 2116
2025
Q1 		$49.4K Buy
15,295
+460
+3% +$2.17K 0.01% 1534
2024
Q4 		$82.6K Buy
14,835
+14,441
+3,665% +$113K 0.01% 1158
2024
Q3 		$4.26K Sell
394
-5,384
-93% -$89.3K ﹤0.01% 1584
2024
Q2 		$121K Buy
5,778
+5,745
+17,409% +$144K 0.02% 884
2024
Q1 		$1.05K Buy
+33
New +$842 ﹤0.01% 1393

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AlphaQuest's FDMT Position: Q1 2026 in Review

AlphaQuest sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 15,731 shares — an estimated $118K sold.

AlphaQuest first reported a position in FDMT in Q1 2024 and held it in 7 quarters. The position peaked at $133K in Q3 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • AlphaQuest reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 15,731 4D Molecular Therapeutics shares in Q1 2026, an estimated $118K.
  • AlphaQuest first reported a position in 4D Molecular Therapeutics in Q1 2024 and held it in 7 quarters.
  • AlphaQuest's 4D Molecular Therapeutics position peaked at $133K in Q3 2025.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.